IBDEI2HC ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39599,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,39600,0)
 ;;=D47.3^^152^2000^64
 ;;^UTILITY(U,$J,358.3,39600,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39600,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,39600,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,39600,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,39601,0)
 ;;=C82.09^^152^2000^65
 ;;^UTILITY(U,$J,358.3,39601,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39601,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39601,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,39601,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,39602,0)
 ;;=C82.00^^152^2000^66
 ;;^UTILITY(U,$J,358.3,39602,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39602,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,39602,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,39602,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,39603,0)
 ;;=C82.19^^152^2000^67
 ;;^UTILITY(U,$J,358.3,39603,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39603,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39603,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,39603,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,39604,0)
 ;;=C82.10^^152^2000^68
 ;;^UTILITY(U,$J,358.3,39604,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39604,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,39604,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,39604,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,39605,0)
 ;;=C82.29^^152^2000^69
 ;;^UTILITY(U,$J,358.3,39605,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39605,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39605,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,39605,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,39606,0)
 ;;=C82.20^^152^2000^70
 ;;^UTILITY(U,$J,358.3,39606,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39606,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,39606,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,39606,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,39607,0)
 ;;=C82.39^^152^2000^71
 ;;^UTILITY(U,$J,358.3,39607,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39607,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39607,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,39607,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,39608,0)
 ;;=C82.30^^152^2000^72
 ;;^UTILITY(U,$J,358.3,39608,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39608,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,39608,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,39608,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,39609,0)
 ;;=C82.49^^152^2000^73
 ;;^UTILITY(U,$J,358.3,39609,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39609,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39609,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,39609,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,39610,0)
 ;;=C82.40^^152^2000^74
 ;;^UTILITY(U,$J,358.3,39610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39610,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,39610,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,39610,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,39611,0)
 ;;=C82.99^^152^2000^75
 ;;^UTILITY(U,$J,358.3,39611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39611,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
